151 related articles for article (PubMed ID: 27037775)
1. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
[TBL] [Abstract][Full Text] [Related]
2. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
[TBL] [Abstract][Full Text] [Related]
3. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Casini N; Forte IM; Mastrogiovanni G; Pentimalli F; Angelucci A; Festuccia C; Tomei V; Ceccherini E; Di Marzo D; Schenone S; Botta M; Giordano A; Indovina P
Oncotarget; 2015 May; 6(14):12421-35. PubMed ID: 25762618
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
5. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
[TBL] [Abstract][Full Text] [Related]
6. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.
Timeus F; Crescenzio N; Fandi A; Doria A; Foglia L; Cordero di Montezemolo L
Oncol Rep; 2008 Feb; 19(2):353-9. PubMed ID: 18202781
[TBL] [Abstract][Full Text] [Related]
7. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
10. Effects of baicalein on proliferation, apoptosis, migration and invasion of Ewing's sarcoma cells.
Ye C; Yu X; Zeng J; Dai M; Zhang B
Int J Oncol; 2017 Dec; 51(6):1785-1792. PubMed ID: 29039470
[TBL] [Abstract][Full Text] [Related]
11. Pyrazolo pyrimidine-type inhibitors of SRC family tyrosine kinases promote ovarian steroid-induced differentiation of human endometrial stromal cells in vitro.
Maruyama T; Yamamoto Y; Shimizu A; Masuda H; Sakai N; Sakurai R; Asada H; Yoshimura Y
Biol Reprod; 2004 Jan; 70(1):214-21. PubMed ID: 14522827
[TBL] [Abstract][Full Text] [Related]
12. Differential effects on cell motility, embryonic stem cell self-renewal and senescence by diverse Src kinase family inhibitors.
Tamm C; Galitó SP; Annerén C
Exp Cell Res; 2012 Feb; 318(4):336-49. PubMed ID: 22197704
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
16. Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages.
Smolinska MJ; Horwood NJ; Page TH; Smallie T; Foxwell BM
Mol Immunol; 2008 Feb; 45(4):990-1000. PubMed ID: 17875324
[TBL] [Abstract][Full Text] [Related]
17. PP2 regulates human trophoblast cells differentiation by activating p38 and ERK1/2 and inhibiting FAK activation.
Daoud G; Le bellego F; Lafond J
Placenta; 2008 Oct; 29(10):862-70. PubMed ID: 18783823
[TBL] [Abstract][Full Text] [Related]
18. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells.
Spreafico A; Schenone S; Serchi T; Orlandini M; Angelucci A; Magrini D; Bernardini G; Collodel G; Di Stefano A; Tintori C; Bologna M; Manetti F; Botta M; Santucci A
FASEB J; 2008 May; 22(5):1560-71. PubMed ID: 18171692
[TBL] [Abstract][Full Text] [Related]
20. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
